A Randomized, Open-Label, Parallel-Group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-Administered in Healthy Subjects.

Trial Profile

A Randomized, Open-Label, Parallel-Group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-Administered in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Bumetanide (Primary) ; Dapagliflozin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 18 Nov 2009 Planned number of patients changed from 648 to 24 as reported by ClinicalTrials.gov.
    • 07 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Nov 2009 Actual patient number (42) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top